Next-generation sequencing is increasingly used in clinical practice for the diagnosis of Mendelian diseases. Because of the high likelihood of secondary findings associated with this technique, the process of informing patients is beset with new challenges. One of them is regarding the type of secondary findings that ought to be disclosed to patients. The aim of this research is to propose a practical implementation of the notion of actionability, a common criteria justifying the disclosure of secondary findings but whose interpretation varies greatly among professionals. We distinguish three types of actionability corresponding to (1) well-established medical actions, (2) patient-initiated health-related actions and (3) life-plan decisions. We argue that actionability depends on the characteristics of the mutation or gene and on the values of patients. In discussing the return of secondary findings, it is important that the physician tries to get an impression of the specific situation and values of patients. Regarding variants of uncertain clinical significance in actionable genes, we found that different understandings of autonomy lead to different conclusions and that, for some of them, it may be legitimate to refrain from returning uncertain information.
- Genetic Information
- Informed Consent
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors CM wrote the first draft. All authors had full access to all the sources in this study and participated in the conception and design of the study, analysis and interpretation of the sources and revision of the manuscript for important intellectual content. All authors approved the final version.
Funding This work was supported by grants from the Käthe-Zingg-Schwichtenberg-Fonds of the Swiss Academy for Medical Sciences and from the Schmidheiny Foundation.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Reclassification of BRCA1 and BRCA2 variants of uncertain significance: a multifactorial analysis of multicentre prospective cohort
- Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification
- Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases
- Comprehensive genetic sequence and copy number analysis for Charcot-Marie-Tooth disease in a Canadian cohort of 2517 patients
- Detection of copy number variants associated with late-onset conditions in ~16 200 pregnancies: parameters for disclosure and pregnancy outcome
- Clinical utility of NGS diagnosis and disease stratification in a multiethnic primary ciliary dyskinesia cohort
- Prospective analysis of 895 patients on a UK Genomics Review Board
- De novo recurrent germline mutation of theBRCA2 gene in a patient with early onset breast cancer
- Variants of Uncertain Significance in BRCA1 and BRCA2 assessment of in silico analysis and a proposal for communication in genetic counselling
- Clinical application of fetal genome-wide sequencing during pregnancy: position statement of the Canadian College of Medical Geneticists